Trius to Present at Future Leaders Conference
02 avr. 2013 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, April 2, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe Skin Infections
25 mars 2013 07h00 HE
|
Trius Therapeutics, Inc.
Tedizolid Met All Primary and Secondary Efficacy Outcomes Designated by the FDA and EMA
NDA Filing Expected Second Half of This Year
SAN DIEGO, March 25, 2013 (GLOBE NEWSWIRE) -- Trius...
Trius Therapeutics Reports 2012 Fourth Quarter and Full Year 2012 Financial Results
12 mars 2013 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, March 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Announces Publication of Tedizolid ESTABLISH 1 Trial in JAMA
12 févr. 2013 16h31 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious...
Trius Therapeutics, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares for Common Stock Offering
23 janv. 2013 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that the underwriters of its previously announced public offering of common stock that priced on...
Trius Therapeutics, Inc. Prices Public Offering of Common Stock
18 janv. 2013 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Jan. 18, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced the pricing of an underwritten public offering of 6,300,000 shares of its common stock at a price...
Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
17 janv. 2013 16h15 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering....
Tedizolid Receives Qualified Infectious Disease Product (QIDP) Designation From FDA
07 janv. 2013 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious...
Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections
10 déc. 2012 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening...
Trius Therapeutics Ranked Number 42 Fastest Growing Company in North America on Deloitte's 2012 Technology Fast 500(TM)
14 nov. 2012 16h01 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...